Melanoma Starts Evading Treatment Within Hours – Here’s How to Stop It
ISB researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.
Featured News
Scientists Decode Diet From Stool DNA – No Questions Asked
ISB’s Gibbons Lab developed a breakthrough method that analyzes food-derived DNA in fecal metagenomes, allowing for data-driven diet tracking without the need for burdensome questionnaires.
More News (Brain Health)
Personalized Coaching Decreases Cognitive Decline in Early-Stage Alzheimer’s Disease Patients
Supplementing the standard of treatment for Alzheimer’s disease patients with personalized lifestyle coaching leads to less cognitive decline compared to standard of treatment alone, according to an ISB-led two-year study. The results were published in the Journal of Alzheimer’s Disease.
Leroy Hood Wants To Show You How To Live for a Really, Really Long Time
Popular Mechanics interviewed ISB Co-founder and Professor Dr. Lee Hood for an article titled “Leroy Hood Wants To Show You How To Live for a Really, Really Long Time.” The story features Hood’s big-data approach and a focus on disease prevention – all in the quest to help us live longer.
COCOA Trial Results Show Diet, Exercise Help Some with Dementia
The recently completed, ISB-led Coaching for Cognition in Alzheimer’s (COCOA) trial shows that diet and exercise can help people suffering from dementia. Senior Research Scientist Dr. Jared Roach discussed the findings in a Research Roundtable presentation.
Coaching for Cognition in Alzheimer’s (COCOA) Clinical Trial Nearly Complete
The multi-year Coaching for Cognition in Alzheimer’s (COCOA) clinical trial is nearly complete. The trial examined diet, exercise and cognitive training as possible non-pharmacological interventions to Alzheimer’s, with some trial members receiving telephonic coaching centered on stress, diet and exercise, as well as brain training focusing on brain speed and attention.
A New Approach to Alzheimer’s Disease
The impact of Alzheimer’s Disease is staggering – 6 million Americans diagnosed, a financial toll of $600 billion annually, and no effective drug treatments. ISB Co-founder Dr. Lee Hood said the traditional approach isn’t working, and we need to think about it in brand new ways.
Bile Acids Provide More Evidence of the Gut Microbiome’s Effect on Alzheimer’s Disease
ISB researchers and their collaborators are looking beyond the one-drug, one-solution approach that has thus far failed in Alzheimer’s disease research. Instead, they are focusing on other promising research avenues, such as the possible role of the gut microbiome in dementia.